Introduction
Recent I )NA cloning studies have revealed the existence of a large family of homologous solute transporters (the 'sugar transporter' family) in organisms as diverse as mammals. plants, fungi and bacteria [ 11. These proteins catalyse the transport of ;I mide range o f substrates. including not only monosaccharides and disaccharides, but also iionsugar molecules such as tricx-boxylic acids and a variety of antibiotics and antiseptic agents [2] . Interestingly, the fhiily contains examples of both passive transporters, typified by the human erythrocyte have proven fruitful, it is clear that a complete understanding of the mechanism of transport at the molecular level will ultimately require determination of the three-dimensional structure of at least one member of the transporter family at atomic resolution. As a possible step towards such a determination, I conclude by describing the development of a system for the large-scale expression of recombinant glucose transporter, which may facilitate crystfallization trials on this protein.
Structural features of the transporter family
W e have exploited the current availability of about SO different amino acid sequences for members of the 'sugar transporter' family to investigate whether, despite their diversity of substrates and transport mechanisms, these proteins exhibit common structural features. Examination of the aligned sequences is valuable because it can reveal features whose significance is not readily appreciated from examination of each sequence in isolation. For example. hydropathy plots of individual sequences suggest the presence of multiple hydrophobic segments in all of the family members, but their exact number and boundaries are often difficult to establish. In contrast, use of the mean values for the aligned sequences yields a much more striking hydropathy plot M ith 12 clearly resolved peaks. presumably corresponding to membrane-spanning segments. 
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-I992 tional evidence for the presence of twelve niembrane-spanning a-helices, and for their sequence locations, is provided by the pattern of the aligned sequences in the transporter family: insertions or deletions are present in at least one rnernber of the family in each of the proposed extramembranous loops connecting the putative transmernbrane helices identified by hydropathic analysis, but are never located within the latter.
'I'he likely presence of twelve menibranespanning a-helices suggests that the members of the transporter family are arranged in the membrane as illustrated in Fig. 1 for the human erythrocyte glucose transporter. Examination of the aligned sequences indicates that several conserved regions in the N-terminal halves of the proteins are repeated in the C-terminal halves, suggesting that an internal gene duplication event occurred during the evolution of the transporters. Consequently. the 12 helices may be arranged in three-dimensions as two domains, each containing a bundle of six helices [ 1 1.
Another characteristic feature of the transporters is the presence of a large hydrophilic region near the centre of the sequence, separating the two putative six-helix domains (Fig. 1) . The predicted cytoplasmic location both of this region and of the hydrophilic C-terminus has been confirmed using vectorial proteolytic digestion [ 1-41 and site-directed anti-peptide antibodies as topological probes of the human erythrocyte glucose transporter [ 15, 16 1.
The extracellular site of glycosylation has also been located on the loop connecting putative trmsniernbrane helices 1 and 2 [ h ] . However, there is as yet little experimental evidence to support the predicted topography of other regions of the protein.
Identification of exofacial lysine residues
In order to obtain additional evidence for the protein topology illustr;lted in I;ig. I . w e have performed vectorial labelling experiments using the membrane-impernieant lysinr-specific reagent, isethionyl acetimidate [ 171. 'I'his reagent was chosen because amidination of proteins can be carried out under mild conditions and because the product, acetimidyl lysine, retains the positive charge of lysine at physiological pI I. W e 1i;ive found that almost complete modification of the Iysine residues of the purified glucose transporter can be achieved without grossly affecting the ability of the protein to bind either the transport inhibitor cytochalasin I< or I )-glucose. lietention of binding activity, and thus of tertiar!, structure, indicates that amidination of the transporter \vould be unlikely to affect its arrangement in the membrane 'I'he inability of the reagent to cross nienibriines M as confirmed by analysis of nienitnines isolated from intact erythrocytes labelled \ I ith rxiioactive isethionylacetiniidate. Sr)S/polyacrylalriiide gel electrophoresis showed that whereas both the anion 
Identification of the substrate binding site(s) of the glucose transporter
Our knowledge of the regions of the glucose transport protein that are involved in substrate translocation is perhaps even more limited than our k n o u ledge of the protein topology. hluch. although not ;ill, of the available evidence supports a model tor sugar translocation in which a sugar binding site(s) is alternately exposed to either the extracellular or cytoplasmic face of the membrane by virtue of :I conformational change [ 1 S, 10 1. I Iow ever, direct information about the location of the substrate-binding site(s), and about the nature of the conforniational change, is minimal. W e have therefore sought to identify the substrate-binding sites in the transporter by photolabelling with two inhibitors of transport, cytochalasin €3 and ATB-BMI'A (Fig. 1) . It is also clear that the site of labelling by this exof;ici;il inhibitor is distinct from that for the endofacial inhibitor. cytochalasin 13, which lies closer t o the C'terniinus, possibly in the region Phe-389-Trp-4 12, which includes the Nterminal half of putative helix 11 1231. These two sites may correspond to outer and inner sugarbinding sites, or to different forms of a single site, which are alternately exposed t o the transported sugar by virtue of a conformational change. A more precise identification of the regions within the sequence labelled by these inhibitors should in the near future clarify the locations of these binding sites. Interestingly, the potent transport inhibitor forskolin and its derivatives are also known to photolabel the C-terminal half of the transporter. at a site(s) suggested to lie within helix 10 1241. It therefore seems likely that this domain of the pro-
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tein contains the substrate-translocation channel, probably involving the amphipathic helices 7, 8 and 11 [6] . The function of the N-terminal domain is unclear.
Functional expression of the glucose transporter in insect cells using a recombinant baculovirus
The experimental approaches outlined above have yielded useful clues to the mechanism of solute transport. Rapid advances in our understanding are also likely to be achieved in the near future through the application of site-directed mutagenesis, because functional expression of small amounts of recombinant mammalian sugar transporters has been achieved both in Xenopus oocytes [25] and in transfected mammalian cells [26] . 1 . Hinding was completely prevented by the presence of 400 m\l-I)-glucose but not by [.-glucose, indicating that the expressed protein bound not only the inhibitor but also the transported substrate. It is therefore clear that human glucose transporter expressed in the baculovirus system exhibits native-like biological activity. The large amounts of protein produced by infected insect cells suggest that the baculovirus expression system will be of great value in the study of structure-function relationships in human erythrocyte and other mammalian glucose transport proteins by site-directed mutagenesis, and for the large-scale production of these proteins for biochemical and mechanistic studies. The recombinant protein may also prove to be more suitable than its native erythrocyte counterpart for crystallization attempts, because it is less heavily and more homogeneously glycosylated. 
